Neuromyelitis optica: clinical features, immunopathogenesis and treatment
نویسندگان
چکیده
منابع مشابه
Immunopathogenesis in Myasthenia Gravis and Neuromyelitis Optica
Myasthenia gravis (MG) and neuromyelitis optica (NMO) are autoimmune channelopathies of the peripheral neuromuscular junction (NMJ) and central nervous system (CNS) that are mainly mediated by humoral immunity against the acetylcholine receptor (AChR) and aquaporin-4 (AQP4), respectively. The diseases share some common features, including genetic predispositions, environmental factors, the brea...
متن کاملClinical features of neuromyelitis optica in children
Objective: To compare clinical features of pediatric neuromyelitis optica (NMO) to other pediatric demyelinating diseases. Methods: Review of a prospective multicenter database on children with demyelinating diseases. Case summaries documenting clinical and laboratory features were reviewed by an adjudication panel. Diagnoses were assigned in the following categories: multiple sclerosis (MS), a...
متن کاملTreatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
BACKGROUND To review our experience using methotrexate as a single long-term immunosuppressant (IS) therapy in neuromyelitis optica/neuromyelitis optica spectrum disorders (NMO/NMOSD). METHODS We performed a retrospective chart review of all patients with a diagnosis of NMO/NMOSD, supported by a positive NMO-IgG testing, who were treated with methotrexate. A paired sample 2 tailed t test was ...
متن کاملDemographic and clinical features of neuromyelitis optica: A review
The comparative clinical and demographic features of neuromyelitis optica (NMO) are not well known. In this review we analyzed peer-reviewed publications for incidence and prevalence, clinical phenotypes, and demographic features of NMO. Population-based studies from Europe, South East and Southern Asia, the Caribbean, and Cuba suggest that the incidence and prevalence of NMO ranges from 0.05-0...
متن کاملTreatment in Neuromyelitis Optica
Background: The effects of interferon1b (IFN1b ) administration in multiple sclerosis (MS) patients have been confirmed, however, those in neuromyelitis optica (NMO) patients have not been shown. In this study, we assessed the effects of IFN1b treatment on disease exacerbation and disability progression in MS or NMO patients. Methods: We reviewed a series of 104 consecutive patients with relaps...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical & Experimental Immunology
سال: 2014
ISSN: 0009-9104
DOI: 10.1111/cei.12271